chevron_leftBack
As of 24 April 2025, Silence Therapeutics plc has a market cap of $144.04M USD, ranking #18844 globally and #438 in the United Kingdom. It ranks #1877 in the Healthcare sector, and #554 in the Biotechnology industry.
Key Stats
Market Cap
$144.04MUSD
Enterprise Value
-$3.18MUSD
Revenue (TTM)
$43.26MUSD
EBITDA (TTM)
-$48.99MUSD
Net Income (TTM)
-$45.31MUSD
EBITDA Margin
-113%
Profit Margin
-105%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Craig Tooman
open_in_new
Employees
116
Founded
1994
Website
silence-therapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 90% | -35% | -37% | -84% | -88% |
Upcoming Earnings
Earnings Date
Thu, May 15
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SLNCF
Silence Therapeutics PLC
ISIN: GB00B9GTXM62
Shares Out.:
Shares Outstanding:
141.674M1
Shares Float:
31.784M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.9500 USD | |
|
NASDAQ
MIC: XNAS
|
SLN
Silence Therapeutics PLC ADR
ISIN: US82686Q1013
Shares Out.:
Shares Outstanding:
47.225M1
Shares Float:
37.561M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.32 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
